Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe in non-alcoholic fatty liver disease under standard diet and exercise therapy
2005-003231-46Phase 2Terminated
- Sponsor
- Medical University of Vienna, Department of Internal Medicine IV
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ezetimibe in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Medical University of Vienna, Department of Internal Medicine IV. Primary endpoint: Change in hepatic lipid content. Started Sep 2005; status: terminated.
02
Drugs
ezetimibe
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2005-003231-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003231-46.